Join to View Full Profile
603 N Flamingo RdSte 151Pembroke Pines, FL 33028
Phone+1 954-265-4325
Fax+1 954-436-4606
Dr. Paba-Prada is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of TennesseeFellowship, Hematology and Medical Oncology, 2007 - 2010
Pennsylvania Hospital of the University of Pennsylvania Health SystemResidency, Internal Medicine, 2004 - 2007
Industrial University of Santander Faculty of MedicineClass of 2000
Certifications & Licensure
FL State Medical License 2009 - 2026
MA State Medical License 2010 - 2022
TN State Medical License 2009 - 2010
PA State Medical License 2004 - 2007
American Board of Internal Medicine Hematology- American Board of Internal Medicine Medical Oncology
Clinical Trials
Publications & Presentations
PubMed
- Tagraxofusp in combination with pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma shows encouraging preliminary efficacy with a manageable ...Paul Richardson, Myo Htut, Emma Scott, Claudia Paba Prada, Ira Gupta
Haematologica. 2025-02-01 - 4 citationsRisk factors for the development of orthostatic hypotension during autologous stem cell transplant in patients with multiple myeloma.Matthew Ho, Maria Moscvin, Soon Khai Low, Benjamin Evans, Sara Close
Leukemia & Lymphoma. 2022-10-01 - 206 citationsTriplet Therapy, Transplantation, and Maintenance until Progression in Myeloma.Paul G Richardson, Susanna J Jacobus, Edie A Weller, Hani Hassoun, Sagar Lonial
The New England Journal of Medicine. 2022-07-14
Abstracts/Posters
- Updated Results of a Phase 2 Study of Modified Lenalidomide, Bortezomib, and Dexamethasone (RVd-lite) in Transplant-Ineligible Multiple MyelomaClaudia E. Paba-Prada, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Results from Phase 1/2 Trial of Tagraxofusp in Combination with Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple MyelomaClaudia E. Paba-Prada, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
